Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
3
×
national top stories
roche
boston
boston blog main
boston top stories
deals
europe top stories
fda
genentech
billy dunn
biogen
biopharma
cancer
cancer immunotherapy
center for medicare and medicaid services
clinical trials
companion diagnostic
daniel o'day
drug prices
drug pricing
duchenne
europe blog main
evrysdi
foundation medicine
foundationone cdx
foundationone heme
gene therapy
ionis pharmaceuticals
licensing
m&a
muscular dystrophy
national
new york blog main
new york top stories
novartis
nusinersen
osimertinib
What
medicine
3
×
roche
3
×
billion
fda
recently
therapy
acquire
agreed
approval
approved
atrophy
betting
big
biopharma
broad
confidence
daily
deal
didn’t
drug
duchenne
evrysdi
foundation
friday
gain
gene
genentech
green
historic
home
intended
lights
liquid
momentum
morning
muscular
new
oral
panels
patients
Language
unset
Current search:
roche
×
medicine
×
" national blog main "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine